Pharmacological Research Communications, VoI. 9, No. 9, 1977
IN VITR 0 BINDING AND METABOLISM OF IOPRONIC ACID BY RAT LIVER MICROSO~S
Elisabetta Raffaeli= Roberto Maffei Facino*~ Mario Salmona**= and Davide Pitt,***.
Istituto di Chimica FarmaceuticajeJTdssicologica viale Abruzzi, 42
201311~i~ano, Italy.
Istituto di Ricerche Farmacologiche "Mario Negri" via Eritrea 62, 20142 Milano, Italy.
***
Laboratori Ricerche Bracco Industria Chimica via Folli 50, 20134 Milano= Italy.
R~eived ~ final form 17 ~ r
S ~ Y
1977
lopronic acid (2-~2-[(3-acetamido-2,4,6-
triiodophenoxy)-ethoxy]- methyl}- butyric acid), a cholecystographic agent= is metabolized by rat liver microsomes to hydroxyethyl-(3-acetamido-2,4=6-triiodophenyl)ether and to 3-acetamido-2~4=6-triiodophenoxy-acetic acid. This metabolism is oxygen- and NADPH-dependent,,and it is inhibited by CO. The addition of iopronic acid to microsomes causes a type II spectral change. The in vitro results are in good agreement with the in vivo data already available showing that iopronic acid is metabolized to a limited extent and that the three iodine atoms present in the parent compound are also found in the metabolites.
833
Pharmacological Research Comrnunications,,Vol: 9, No, 9, 1977
834
INTRODUCTION
The hepatic microsomalmixed-function oxidase system is known to metabolize a wide variety of substrafes bo>h of endogenous and exogenous origin~ most of whiQh combine with hepatic microsomal P-450 to produc~ spectral changes of type I or II (Mannering~ 197~; Mailman et al.~ 1974). Although the ability of c o m p o u n d s to bind with cytochrome P-450 does n o t guarantee their metabolism and v!.ceversa , it is always interesting to investigate whether or not chemicals which are clearly metabolized through an oxidative pathway might be capable of combining with cytochrome P-450 (Imai and S a t o s 1967; Jefcoate and Gaylor, 1969; Jefcoate, Gaylor and Calabrese, 1969). lopronic acid (IA) (Pitr~ and Maffei Facino, 1976), an orally active cholecystographic agent widely used in radiological diagnostic examination of biliary ducts, has been shown to be metabolized by rat liver microsomal preparations. The two metabolites found, hydroxyethyl-(3-acetamido-2,4,6-triiodophenyl)-ether (HPE) and 3-acetamido-2~4~6-triiodophenoxy-acetic acid (PAA), arise from oxidative cleavage of the side chain of IA (Fig.l). In this paper we present data confirming that cytochrome P-450 is directly involved in the biotransformation of IA.
MATERIALS AND M E T H O DS All the organic solvents used were of analytical grade. The iopronic acid(IA) was batch N. 46/c (Bracco S.p.A.) NADP~ glucose-6-phosphate (G-6-P) and glucose-
Pharmacological Research Communications, Do/. 9, No. 9, 1977 -6-phosphate dehydrogenase
and phospholipase C were
purchased from Boehringer~ Mannheim, Germany. Homogenization was carried out in a Potter Elvehjem glass tube with a Teflon pestle. Centrifugation was at IO~O00 X g in a Sorvall Rc-5 centrifuge and at iO5~OO0 x g in a Spinco model L ultracentrifuge. Incubations were performed in a Dubn0ff metabolic ~ shaker at 37°C.
Ti ssue preparation ~le
Wistar rats (200-250 g) were used through-
out this study. The animals were killed by a blow to the head and the livers were excised and placed in cold 1.15% KCI. The livers were then minced and homogenized with 3 vol. of a 2:1 solution of 1.15% KCI and 0.2 M phosphate buffer~ pH 7.4. The homogenates were centrifuged at IO,O00 x g for 20 min. tO remove cell debris~ nuclei and mitochondria~ and the supernatants recentrifuged at IO5~OOO x g for 1 h. The microsomal pellet was suspended in a volume of O.I M phosphate Duffer pH 7.4 to give a suspension containing 8.5 mg of protein/ml. Protein was determined by the method of Lowry et al. (1951)~ using bovine serum albumin (Fluka-Swiss) as standard.
For studies of druK metabolism (Fig. i-3) Incubation mixtures Samples of the microsomal suspension were incubated for 60 min., with shaking, at 37°Cj in an atmosphere of oxygen. Each ml of incubation mixture contained 8,5 mg of microsomal protein, 2.5 }/tool of NADP, 20 nmol of MgCI2, 40~=nol of G-6-P, 5 units of G-6-P dehydrogenase
835
836
Pharmacological'Research CommUnications,. VoL 9, No. 9, 1977
and 62.O2~noi of IA. Triplicate
10 ml aliquots were incu-
bated in each experiment. Control samples conlsisted of microsomes inactivated by heating at 60°C per 5 min. At zero time the flasks were placed in the metabolic shaker and allowed to preincubate for 5 min.~ with shaking to ensure adequate starting concentrations
CI2H5 .OCH2CH2OCH2-CH-COOH
't@I'
of NADPH.
2 1~[(3-Acetamido- 2. 4. 6- tr,,odophenoxy} -ethoxy]-methy{ l-butyric ac,d
NHCOCH3
I
OCH2CH20H
't@'
Hydr oxyet hy|- ( 3-Acetamtdo-2,4.6-triiodop~enyl) ether (HPE)
NHCOCH3
!
OCH2COOH
I.~. I
3 - a c e t a m i d o - 2,4.6-lr,iodophenoxy -acetic acid (PAA)
"NHCOCH3 1 Figure 1 :
Structure of iopronic acid and its metabolites.
Extraction The incubation mixtures were adjusted to pH 1.5 with conc. HCI and extracted 4 times for 5 min. with 4
volumes of diethylether. The ether e×tracts were concentrated under vacuum
and the residuess
taken up in 0.5 ml of methanol s were
assayed.for quantitative determination of iopronlc acid and its metabolites
(Pitr~ and Felder s 1976).
Pharrnacologica/ Research Communications, L/o/. 9, No. 9, 1977
837
Aqueous residues from the incubation mixtures were tested for the presence of inorganic iodide (Pitr~ and Maffei Facino,1976).
elm
•~
75 6o
E
C
0
30
60
90
120 rain.
-o c
E'S
3~.
20-
oE ,o -
"
0
..............
I
.
.
.
.
.
30
Figure 2 :
'
I
"
--
60
-
|
.
.
.
.
.
.
.
.
90
-
•
.
.
.
.
.
.
120 min
Time course of IA metabolism by rat liver cromosomes° Experimental
conditions are described
in the text. Each point representsthe mean + S.E. of four different determinations. x
x
= unchanged IA = HPE
•
For~studies
•
=PAA
of substrate binding (Fig. 4,5)
I) Gytochrome P-450 content Microsomal
cytochrome P-450 was determined by
its carbon monoxide difference
spectrum after reduction
Pharmacologicat~Research Communications, Vol. 9, No. 9, 1977
838
with Na2S204. Cytochrome P-450 contenO was measured on a model 25 Beckman spectrophotometer ence in absorbance
by the differ-
between 450-490 nm 3 Using the
extinction coefficient
of 91 mM -1 cm -1 (Schenkman
and Sato,1968),In all the experiments~
the concentration
of microsomal P-450 was 0,522± 0.070 nmol/mg of protein (Curve 1 Fig. 5),
20"
10
0 Fi gure 3 :
•
|
30
60
1
|
120 min.
90
Dependence of IA metabolism on liver microsomal monooxygenases.
Each point
representsthe mean ~ S.E, of four different experiments. x
x
= incubation in the presence of NADPH and 02
A
A
= incubation in the absence of NADPH and 02
•
= incubation in the pres-~ ence of NADPH after replacement of 02 with CO.
" 'a Pharmacotogm I Research Communications, VoL 9, No. 9, 1977
839
2) S__ubstrate bindin~ a) Aerobic substrate binding Spectra were determined between 500 and 350 n m w i t h the Beckman model 25 spectrophotometer.Difference
binding
spectra were obtained at room temperature.All cuvettes contained 2.5 ml of a suspension of 8.5 mg of microsomal protein/ml in O.l M phosphate buffer.The sample cuvette also contained 2.5~Jmol of
IA in lO~ul of methanol and
the reference cuvette contained IO ~I of methanol. B6th cuvettes were
gently inverted 5 times and then
left to equilibrate in
the sample chamber for I min.
before scanning (Fig.4).
U
J~
,i
i
i
lie
soo w A w u ~ ' ~ (n,n)
Figure 4:
Spectral change observed agter addition of 2.5 ~mol of IA to the sample cuvette.
(X max
425, /(
395)
Experimental conditions as in the text.
Pharmacological'Research Communications,...VoL 9, No. 9;. 1977
840
b) Dependence on substrate concentration The study of the dependence of the binding on substrate concentration was performed as described above~ adding to the sample cuvette 1.25, 2.5, 5.0 or
7.5 ~nol
of IA (Table I), i
TABLE I Intensity of IA difference spectra at various drug concentrations
~A(425_500)/mgof
Amount of IA added to the sample
protein
cuvette
0=oi ) ,
,,,
_
,,,,
1.25
0.0025 ÷ 0.00022
2.5
0.0030 ~0.00031
5.O
0.0042 + 0.00015
7.5
0.0045 + 0.00097
Each figure is the mean ~ S. E. of three different determinations.Details are given under
of experimental
conditions
"Materials and Methodos".
c) Substrate binding to reduced cytochrome The 2.5 ml of microsomal cuvettes were reduced with an excess of dithionite. then added IA ( 7 . 5 ~ o i ) ,
suspension in both
7.5~moI
NADPH or with
To the sample cuvette was as described in section 2a.
d) Interaction of IA with dithionite-reduced
P-450-CO
complex 2.5)amol of IA in methanol were added to 2.5 ml microsomal
suspension in O.I M phosphate buffer.
Pharmaco/ogical Research Communications, Vol. 9, No. 9, 1977 The cytochrome
841
P-450 had been reduced by addition of
an excess of Na dithionite. CO was bubbled through
the
sample cuvette for 2 min. The reference cuvette contained dithionite but no CO (curve 2~ fig. 5). e) Binding to phospholipase C-treated microsomes The methodology used for phospholipase C incubation
Opticat density i
0.3.
1 0.2" 2
0.1
|
400 Figure 5:
-
i
w
WAVELENGTH
i
•
(nm)
600
Effect of IA on the dithionite-reduced P-450
spectrum.
Curve I, without drug;curve 2, after addition of 2 . 5 ~ o i
of IA.
Experimental conditions as in the text.
Pharmacological" Research.Communications, VoL 9, No. 9, 1977
842
was that of Chaplin and Mannering (1970). At the end of the incubation period £he cytochrome P-450 content was again determined: phospholipase C treatment caused a loss of about 25% of cytochrome 2-450. ,Binding studies were performed as described in section (2a) above.
RESULTS The time course of iopronic acid metabolism by t
rat liver microsomes is shown ~ in Fig. 2. Time studies of incubatidn o~ iopr6nic acid with rat liver microsomes showed a linear increase ,in the amount of HPE and PAA formed between i anti 90 min. After 90 min. ~ whenl the amount of IA metabolites represent 22% of the unchanged drug~ no further increase occurred. Replacement of 02 with an 02 + CO atmosphere (IO :' 90), Which is known to inhibit the hepatic microsomal m i x e d - f u n c , t i o n
oxidase
(Conney ed a l . ,
1957), result-
1
ed i n a c o n s i d e r a b l e
decrease
in the metabolism
of
t
iopronic
acid
(Fig.,' 3).
I n t h e same way, t h e a b s e n c e
i
in the incubation
mixture
of an
NADPH-generating p
produced a marked decrease
'system
~
in the metabolism
of iopronia
acid.
Binding of IA to hepatic micros0ma ~ P-450
Type of spectra
The addition of IA as substrate for the microsomal mixed-function oxidase system to aerobic liver microsomes causes a type II spectral change, characterized by the appearance of an absorption peak at 425 nm and a trough at 395 nm (Fig. 4).
Pharmacological Research Communications, 1/ol. 9, No. 9, 1977 DI SC,,USSI ON The dependence of the IA metabolism on 02 and NADPH and its inhibition by CO demonstrate the involvement of the NADPH-dependent mixed-function oxidase system. The molecular specificity of type II binding exhibited by IA also confirms the role of the mixed-functlon oxidase system in the biotransformation of this compound. !n vitro experiments carried out with IA added to rat liver microsomal preparations indicate that the drug is metabolized only to a limited extent. The metabolites~ HPE and PAA~ are formed at the same rates, although larger quantities of HPE are found. This is in agreement with data already available in man. Pitr~ and Felde= (1976)~ in fact~ reported that only 8% of the administered dose is excreted as PAA and HPE in urine in the first 48 hours. The fact that the two metabolites still contain the three iodine atoms present in the parent compound indicates that the C-I bonds of the molecule are not involved in the oxidative pathway. Furthermore, our own analyses for the presence of free iodide show that during incubation no iodine leakage occurred in the incubation mixture. This fact~ together with the limited extent of the metabolism, indicate from a pharmacological point of view that IA seems to fulfil some of the requirements for a cholecystographic agent. As reported in table I~ the magnitude of the spectral change observed depends on the concentration of substrate added to the microsomal suspension. Like aniline~ a type II substrate (Schenknmn et al.~
843
Pharmacological'Research Communications, Vo/. 9, No. 9, 1977
844
TABLE
II
Effect of reducing agents (NADPH and dithionite) and phospholipase C-treatment on iopronic acid binding to P-450.
CUVETTE CONTENT Reference
Microsomal
suspension
Sample
~A(425-500)/rag of protein
Microsomal suspension
0.0045 + 0.O01
+ 7,5 2~mol IA
Microsomal suspension + 7.5 ~mol NADPH
Mi crosomal suspension
O. 0020 + O. 0002
+ 7.5 ~umol NADPH + 7.5)xnol IA
Microsomal suspension
Microsomal suspension
+ Na2S204 in excess
+ Na2S204 in excess + 7.5 )~nol IA
Phospholipase C-treated
Phospholipase C-treated
microsomes
microsomes + 7.5~moI
0.0025 + 0.0003
IA
The data are the means + S.E. of three different determinations. Details of experimental conditions are given under "Materials
and Methods".
1973), IA interacts with ferricytochrome P-450 and displaces carbon monoxide from the dithionite-reduced P-450. The extent to which-IA interacts with dithionite-reduced P-450 is evident in Fig. 5" from the magnitude
Pharmacological Research Communications, Vol..9, No. 9, 1977 of the decrease in the CO-complex spectrum. Equally,the addition af an equimolecular amount of NADPH to micra_ somes in the presence of IA causes a decrease in the absorption peaks of the binding spectra~ while the addition of an excess of the chemical reductant sodium dithionite obliterates the IA-induced spectral changes (Table II)• as previously described by Schenkman et al. (1967)for other type II substrates. As further proof that IA give s type II binding spectra• we studied the binding of IA to phospholipase C-treated microsomes•
since this agent is known to
destroy type I binding spectra but not type II (Chaplin and Mannering•
1970).
The results obtained show that IA binding fz not destroyed by such treatment ~Table Ill• even though the strength of binding is less than the initial strength because of partial denaturation of the cytochrome P-450 by phosphollpase C.
REFERENCES CHAPLIN M.D., and MANNERING G.J., Mol. Pharmacol. 6, 631 (1970). CONNEY A.H. ~ BROWN R.R. ~ MILLER J.A. and MILLER E.C., Cancer Res., 17~ 628 (1957). IMAI Y. and SATO R.~ J. Biochem.
(Tokyo)• 62•
239, (1967). JEFCOATE C.R. and GAYLOR J.L.~ Biochemistry N.Y., _Sj 3464 (1969). JEFCOATE C.R. 3 GAYLOR J.L. • CALABRESE R.L. • Biochemistry N.Y.• 8• 3455 (1969).
845
846
Pharmacological'Research Communications, VoL :9, No. 9, 1977
LOWRY O.H.,ROSEBNOUOH N.J., FARR A.L. and RANDALL R.J., Jo Biol. Chem., 193, 265 (1951). MAILMAN R.B., KULKARNI A.P., BAKER R.C. and HODGSON E., Drug Metab. Dispos., 2~ 301 (1974). MANNERING G.J., Fundamental of Drug Metabolism and Drug Disposition, (Eds. La Du B°N.~ Mandell H. G. and Way E.L.) p. 206, Williams and Wilkins, Baltimore (1971).
PITRE D. and FELDER E., Farmaco ed. prat., 31~ 540 (1976). PITRE D° and MAFFEI FACINO R.~ Farmaco ed. sci°~ 31, 755 (1976). SCHENKMAN J.B., CINTI D.L., MOLDEUS P.W. and ORRENIUS S.~ Drug Metab. Dispos., _I, IIi (1973). SCHENKMAN J.B., REMMER H., ESTABROOK R.W. ~ Mol. Pharmacol.~ 3, 113 (1967). SCHENKMAN J.B. and SATO R., Mol. Pharmacol., _4~ 613 (1968).